['NA \xe2\x80\x93 NOT AVAILABLE/REPORTED', 'DIGOXIN CONCENTRATIONS INCREASED > 50%', '', 'DIGOXIN\xc2\xa0SERUM CONCENTRATION INCREASE', 'DIGOXIN\xc2\xa0AUC INCREASE', 'RECOMMENDATIONS', 'AMIODARONE', '70%', 'NA', 'MEASURE SERUM DIGOXIN CONCENTRATIONS BEFORE INITIATING CONCOMITANT DRUGS. REDUCE DIGOXIN CONCENTRATIONS BY DECREASING\xc2\xa0DOSE\xc2\xa0BY\xc2\xa0APPROXIMATELY 30% TO 50% OR BY MODIFYING THE DOSING FREQUENCY AND CONTINUE MONITORING.', 'CAPTOPRIL', '58%', '39%', 'CLARITHROMYCIN', 'NA', '70%', 'DRONEDARONE', 'NA', '150%', 'GENTAMICIN', '129-212%', 'NA', 'ERYTHROMYCIN', '100%', 'NA', 'ITRACONAZOLE', '80%', 'NA', 'NITRENDIPINE', '57%', '15%', 'PROPAFENONE', 'NA', '60-270%', 'QUINIDINE', '100%', 'NA', 'RANOLAZINE', '50%', 'NA', 'RITONAVIR', 'NA', '86%', 'TETRACYCLINE', '100%', 'NA', 'VERAPAMIL', '50-75%', 'NA', 'DIGOXIN CONCENTRATIONS INCREASED < 50%', 'ATORVASTATIN', '22%', '15%', 'MEASURE SERUM DIGOXIN CONCENTRATIONS BEFORE INITIATING CONCOMITANT DRUGS. REDUCE DIGOXIN CONCENTRATIONS BY DECREASING THE DOSE BY APPROXIMATELY 15% TO 30% OR BY MODIFYING THE DOSING FREQUENCY AND CONTINUE MONITORING.', 'CARVEDILOL', '16%', '14%', 'DILTIAZEM', '20%', 'NA', 'INDOMETHACIN', '40%', 'NA', 'NEFAZODONE', '27%', '15%', 'NIFEDIPINE', '45%', 'NA', 'PROPANTHELINE', '24%', '24%', 'QUININE', 'NA', '33%', 'SAQUINAVIR', '27%', '49%', 'SPIRONOLACTONE', '25%', 'NA', 'TELMISARTAN', '20-49%', 'NA', 'TOLVAPTAN', '30%', 'NA', 'TRIMETHOPRIM', '22-28%', 'NA', 'DIGOXIN CONCENTRATIONS INCREASED, BUT MAGNITUDE IS UNCLEAR', 'ALPRAZOLAM, AZITHROMYCIN, CYCLOSPORINE, DICLOFENAC, DIPHENOXYLATE, EPOPROSTENOL, ESOMEPRAZOLE, IBUPROFEN, KETOCONAZOLE, LANSOPRAZOLE, METFORMIN, OMEPRAZOLE, QUININE, RABEPRAZOLE,', 'MEASURE SERUM DIGOXIN CONCENTRATIONS BEFORE INITIATING CONCOMITANT DRUGS. CONTINUE MONITORING AND REDUCE DIGOXIN DOSE AS NECESSARY.', 'DIGOXIN CONCENTRATIONS DECREASED', 'ACARBOSE, ACTIVATED CHARCOAL, ALBUTEROL, ANTACIDS, CERTAIN CANCER CHEMOTHERAPY OR RADIATION THERAPY, CHOLESTYRAMINE, COLESTIPOL, EXTENATIDE, KAOLIN-PECTIN, MEALS HIGH IN BRAN, METOCLOPRAMIDE, MIGLITOL, NEOMYCIN, PENICILLAMINE, PHENYTOIN, RIFAMPIN, ST.\xc2\xa0JOHN\xe2\x80\x99S WORT, SUCRALFATE, SULFASALAZINE', 'MEASURE SERUM DIGOXIN CONCENTRATIONS BEFORE INITIATING CONCOMITANT DRUGS. CONTINUE MONITORING AND INCREASE DIGOXIN DOSE BY APPROXIMATELY 20 % TO 40 % AS NECESSARY.', 'NO SIGNIFICANT DIGOXIN EXPOSURE CHANGES', 'PLEASE\xc2\xa0REFER\xc2\xa0TO\xc2\xa0SECTION\xc2\xa012\xc2\xa0FOR\xc2\xa0A\xc2\xa0COMPLETE\xc2\xa0LIST\xc2\xa0OF\xc2\xa0DRUGS\xc2\xa0WHICH WERE STUDIES BUT REPORTED NO SIGNIFICANT CHANGES ON DIGOXIN EXPOSURE.', 'NO\xc2\xa0ADDITIONAL\xc2\xa0ACTIONS\xc2\xa0ARE\xc2\xa0REQUIRED.']